S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
BREAKING: Tiny biotech successfully treats blindness (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
BREAKING: Tiny biotech successfully treats blindness (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
BREAKING: Tiny biotech successfully treats blindness (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
BREAKING: Tiny biotech successfully treats blindness (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
NASDAQ:KERX

Keryx Biopharmaceuticals (KERX) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.97
▼
$3.47
50-Day Range
N/A
52-Week Range
$2.47
▼
$5.98
Volume
2.60 million shs
Average Volume
1.69 million shs
Market Capitalization
$344.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media

KERX stock logo

About Keryx Biopharmaceuticals (NASDAQ:KERX) Stock

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Receive KERX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KERX Stock News Headlines

May 12, 2023 | marketwatch.com
8-K: CUTERA INC
May 6, 2023 | seekingalpha.com
Manoj Madhavan
May 28, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 3, 2023 | finance.yahoo.com
Biopharmaceuticals Market Size [2023-2030] | Industry Share, Revenue, Key Players, CAGR, Demand and Forecast
April 13, 2023 | wsj.com
Staidson (Beijing) Biopharmaceuticals Co. Ltd.
March 28, 2023 | finance.yahoo.com
Biopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight Partners
January 29, 2023 | marketwatch.com
Biopharmaceuticals Market 2023 Analysis by Market Size, New Technology, Growth Rate, Geographical Regions, Drivers and Outlook to 2027
January 25, 2023 | seekingalpha.com
NAVB Navidea Biopharmaceuticals, Inc.
May 28, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
January 25, 2023 | finance.yahoo.com
Biopharmaceuticals Contract Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)
September 15, 2022 | thestreet.com
Well-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug Launch
October 26, 2021 | finance.yahoo.com
Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat
July 29, 2021 | au.finance.yahoo.com
Twitter tests notification banner for suspended and locked accounts
July 29, 2021 | yahoo.com
Joey Jordison, Slipknot co-founder and longtime drummer, dies at age 46
July 28, 2021 | uk.finance.yahoo.com
Why Starbucks (SBUX) Might Surprise This Earnings Season
July 27, 2021 | uk.finance.yahoo.com
UN: World leaders can attend annual UN meeting in person
July 27, 2021 | nz.finance.yahoo.com
Creekstone Farms Meats Sizzle on Yoder Smokers With New Partnership
July 27, 2021 | au.finance.yahoo.com
Midtown, Atlanta Based Innovien Solutions Continues Growth Streak
July 27, 2021 | nz.finance.yahoo.com
Jill Biden Made This Versatile Bag Sell Out, and She Just Wore It Again
July 27, 2021 | yahoo.com
It's Your Business | More improvements on tap for Target on North Prospect
July 12, 2021 | reuters.com
Keryx shareholder can't revive lawsuit over pill production halt
June 20, 2021 | ca.finance.yahoo.com
Triggerfish CEO Stuart Forrest on How African Animation Has Found Its Moment
June 20, 2021 | finance.yahoo.com
Akebia Therapeutics, Inc. (AKBA)
April 29, 2021 | benzinga.com
Renal Diseases
August 19, 2020 | markets.businessinsider.com
Keryx Biopharmaceuticals CHART
June 10, 2020 | www.bloomberg.com
Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA
April 30, 2020 | seekingalpha.com
SCYNEXIS, Inc. (SCYX)
See More Headlines

Receive KERX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KERX Company Calendar

Last Earnings
11/08/2018
Today
5/28/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:KERX
CUSIP
49251510
CIK
1114220
Web
www.keryx.com
Phone
617-466-3500
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-163,440,000.00
Net Margins
-96.41%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-60.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.21
Quick Ratio
1.19

Sales & Book Value

Annual Sales
$60.64 million
Price / Sales
5.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-28.00

Miscellaneous

Outstanding Shares
102,380,000
Free Float
N/A
Market Cap
$344.00 million
Optionable
Optionable
Beta
2.35

Key Executives

  • Ms. Jodie Pope Morrison (Age 43)
    Interim CEO & Director
  • Mr. Scott A. Holmes (Age 44)
    CFO, Sr. VP & Treasurer
  • Ms. Christine A. Carberry (Age 57)
    Sr. VP & COO
  • Dr. John F. Neylan (Age 65)
    Sr. VP & Chief Medical Officer
  • Mr. Tony Chambers
    VP of Sales

Key Competitors

View All Competitors













KERX Stock - Frequently Asked Questions

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) issued its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to analyst estimates of $29.56 million.

What other stocks do shareholders of Keryx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Immunomedics (IMMU), Novavax (NVAX), Akebia Therapeutics (AKBA), Ariad Pharmaceuticals (ARIA), Chesapeake Energy (CHKAQ) and Celldex Therapeutics (CLDX).

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

What is Keryx Biopharmaceuticals' stock price today?

One share of KERX stock can currently be purchased for approximately $3.36.

How much money does Keryx Biopharmaceuticals make?

Keryx Biopharmaceuticals (NASDAQ:KERX) has a market capitalization of $344.00 million and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How can I contact Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The official website for the company is www.keryx.com. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at investors@keryx.com.

This page (NASDAQ:KERX) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -